STOCK TITAN

PREVECEUTICAL MEDICAL INC - $PRVCF STOCK NEWS

Welcome to our dedicated page for PREVECEUTICAL MEDICAL news (Ticker: $PRVCF), a resource for investors and traders seeking the latest updates and insights on PREVECEUTICAL MEDICAL stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PREVECEUTICAL MEDICAL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PREVECEUTICAL MEDICAL's position in the market.

Rhea-AI Summary

PreveCeutical Medical Inc. announces a Management Cease Trade Order due to missing the deadline for filing annual financial statements. The Company applied for a MCTO as a result of a lack of funds preventing completion of the audit on time. PreveCeutical expects to file the Annual Filings by June 28, 2024, and will provide bi-weekly default status reports until then. Additionally, the Company plans a private placement to raise $250,000 for working capital purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.14%
Tags
none
-
Rhea-AI Summary
PreveCeutical Medical Inc. (PREV) has started preparations to accelerate completion of its preclinical dual gene therapy program using its developed Smart-siRNA sequences and proprietary bioresponsive lipid-nanoparticulate delivery systems. The company has received interest from a world-leading pharmaceutical company for its diabetes & obesity dual gene therapy program and is seeking funding to complete preclinical studies, with plans to commence in early 2024. CEO Stephen Van Deventer expressed excitement over the validation of their research program and the global need for diabetes and obesity therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20%
Tags
-
Rhea-AI Summary
Endosane Pharmaceuticals will conduct preclinical studies to evaluate the brain delivery characteristics of sol-gel technology and CBD. The study aims to assess the amounts achieved, regional distribution, and time course of CBD uptake in the brain. The research proposal includes experiments on rats to demonstrate the pharmacological relevance of brain CBD concentrations. Collaborative efforts with the University of Sydney have identified anandamide as a potential blood surrogate marker for CBD's brain activity. PreveCeutical and Endosane's dedication to research in CBD delivery and pharmacology shows their commitment to advancing medical knowledge. No concrete business takes affecting stock price are mentioned.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.73%
Tags
none
Rhea-AI Summary
PreveCeutical showcases dynamic evolution in AI strategy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
AI
-
Rhea-AI Summary
PreveCeutical Medical Inc. has entered into a Service Agreement with New to the Street Group LLC for production and broadcasting services involving television, production, media analysis, and procurement. The agreement includes a total compensation of $150,000, with the first payment of $5,000 due by September 15, 2023, and the remaining five payments of $5,000 due on the 1st of each consecutive month. The term of the agreement is from September 1, 2023, to February 29, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.11%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.95%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.5%
Tags
none
PREVECEUTICAL MEDICAL INC

OTC:PRVCF

PRVCF Rankings

PRVCF Stock Data

9.78M
391.00M
24.09%
General Medical and Surgical Hospitals
Health Care and Social Assistance
Link
United States of America
Vancouver